Investor Presentation March 2023
Inotiv's Business Segments
Total Revenue by Type
(TTM Dec 31)
Preclinical
Services
Other
2%
38%
Large
Animal
36%
Small
Animal
Teklad
9%
15%
•
Discovery and Safety Assessment (DSA)
Key offerings are centered in pharmacology, toxicology, DMPK, histopathology, plus centers of expertise in
surgical models and medical device testing; with associated access to experienced consulting team
Supports the needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and
medical devices, from Discovery to Preclinical Development and through phased clinical assessments
Strong backlog and book to bill
Research Models and Services (RMS)
Key offerings include large and small research models, Teklad diets, bedding, genetic modification
services and other support services
Supports CRO, academic, pharma, & government customers through delivery of genetically consistent
research models
Long-standing, dependable supplier relationships with critical suppliers across an international logistics
network
High revenue retention rate (>99%)
Incredibly durable customer relationships (17 of top 20 customers have been repeat customers for 10+
years)
6View entire presentation